<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37636591</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1536-0121</ISSN><JournalIssue CitedMedium="Internet"><Volume>2023</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Molecular imaging</Title><ISOAbbreviation>Mol Imaging</ISOAbbreviation></Journal><ArticleTitle>PET and SPECT Imaging of ALS: An Educational Review.</ArticleTitle><Pagination><StartPage>5864391</StartPage><MedlinePgn>5864391</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5864391</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2023/5864391</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a disease leading to progressive motor degeneration and ultimately death. It is a complex disease that can take a significantly long time to be diagnosed, as other similar pathological conditions must be ruled out for a definite diagnosis of ALS. Noninvasive imaging of ALS has shed light on disease pathology and altered biochemistry in the ALS brain. Other than magnetic resonance imaging (MRI), two types of functional imaging, positron emission tomography (PET) and single photon emission computed tomography (SPECT), have provided valuable data about what happens in the brain of ALS patients compared to healthy controls. PET imaging has revealed a specific pattern of brain metabolism through [<sup>18</sup>F]FDG, while other radiotracers have uncovered neuroinflammation, changes in neuronal density, and protein aggregation. SPECT imaging has shown a general decrease in regional cerebral blood flow (rCBF) in ALS patients. This educational review summarizes the current state of ALS imaging with various PET and SPECT radiopharmaceuticals to better understand the pathophysiology of ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Ayaan M. Jamali et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jamali</LastName><ForeName>Ayaan M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0009-0008-9613-8552</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kethamreddy</LastName><ForeName>Manasa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burkett</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials><Identifier Source="ORCID">0000-0002-0457-5712</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Port</LastName><ForeName>John D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-4237-7776</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandey</LastName><ForeName>Mukesh K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0002-2332-5305</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Imaging</MedlineTA><NlmUniqueID>101120118</NlmUniqueID><ISSNLinking>1535-3508</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>29</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>4</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37636591</ArticleId><ArticleId IdType="pmc">PMC10460279</ArticleId><ArticleId IdType="doi">10.1155/2023/5864391</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown R. H., Al-Chalabi A. Amyotrophic lateral sclerosis. New England Journal of Medicine . 2017;377(2):162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedermeyer S., Murn M., Choi P. J. Respiratory failure in amyotrophic lateral sclerosis. Chest . 2019;155(2):401&#x2013;408. doi: 10.1016/j.chest.2018.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2018.06.035</ArticleId><ArticleId IdType="pubmed">29990478</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott E. O., Malek A. M., Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handbook of Clinical Neurology . 2016;138:225&#x2013;238. doi: 10.1016/B978-0-12-802973-2.00013-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-802973-2.00013-6</ArticleId><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei S., Carr K., Reiley L., et al. A comprehensive review of amyotrophic lateral sclerosis. Surgical Neurology International . 2015;6:p. 171. doi: 10.4103/2152-7806.169561.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2152-7806.169561</ArticleId><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G., Traynor B. J., Hardiman O., et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. Journal of Neurology, Neurosurgery &amp; Psychiatry . 2008;79(1):6&#x2013;11. doi: 10.1136/jnnp.2006.104828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.104828</ArticleId><ArticleId IdType="pubmed">18079297</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M. R., Hammers A., Al-Chalabi A., et al. Distinct cerebral lesions in sporadic and &#x2018;D90A&#x2019; SOD1 ALS: studies with [11C]flumazenil PET. Brain . 2005;128(6):1323&#x2013;1329. doi: 10.1093/brain/awh509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh509</ArticleId><ArticleId IdType="pubmed">15843422</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: a clinical review. European Journal of Neurology . 2020;27(10):1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis A. M., Groen E. J., Koppers M., van den Berg L. H., Pasterkamp R. J. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathologica . 2013;125(6):777&#x2013;794. doi: 10.1007/s00401-013-1125-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1125-6</ArticleId><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S., Stauffer J. E., Schulte D. J., Ravits J. Neuropathology of amyotrophic lateral sclerosis and its variants. Neurologic Clinics . 2015;33(4):855&#x2013;876. doi: 10.1016/j.ncl.2015.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.012</ArticleId><ArticleId IdType="pmc">PMC4628785</ArticleId><ArticleId IdType="pubmed">26515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith B., Newhouse S., Shatunov A., et al. The C9ORF72 expansion mutation is a common cause of ALS+/&#x2212;FTD in Europe and has a single founder. European Journal of Human Genetics . 2013;21(1):102&#x2013;108. doi: 10.1038/ejhg.2012.98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2012.98</ArticleId><ArticleId IdType="pmc">PMC3522204</ArticleId><ArticleId IdType="pubmed">22692064</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I. R., Boeve B. F., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron . 2011;72(2):245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R., Isaacs A. M. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nature Reviews Neurology . 2018;14(9):544&#x2013;558. doi: 10.1038/s41582-018-0047-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. The Lancet Neurology . 2011;10(3):253&#x2013;263. doi: 10.1016/S1474-4422(11)70015-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70015-1</ArticleId><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Frontiers in Immunology . 2017;8:p. 1005. doi: 10.3389/fimmu.2017.01005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Schain M., Kreisl W. C. Neuroinflammation in neurodegenerative disorders-a review. Current Neurology and Neuroscience Reports . 2017;17(3):p. 25. doi: 10.1007/s11910-017-0733-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-017-0733-2</ArticleId><ArticleId IdType="pubmed">28283959</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefera T. W., Steyn F. J., Ngo S. T., Borges K. CNS glucose metabolism in amyotrophic lateral sclerosis: a therapeutic target? Cell &amp; Bioscience . 2021;11(1):p. 14. doi: 10.1186/s13578-020-00511-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13578-020-00511-2</ArticleId><ArticleId IdType="pmc">PMC7798275</ArticleId><ArticleId IdType="pubmed">33431046</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambhir S. Molecular imaging of cancer with positron emission tomography. Nature Reviews Cancer . 2002;2(9):683&#x2013;693. doi: 10.1038/nrc882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc882</ArticleId><ArticleId IdType="pubmed">12209157</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro A., Pagani M., Montuschi A., et al. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. European Journal of Nuclear Medicine and Molecular Imaging . 2014;41(5):844&#x2013;852. doi: 10.1007/s00259-013-2667-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-013-2667-5</ArticleId><ArticleId IdType="pmc">PMC8957062</ArticleId><ArticleId IdType="pubmed">24445987</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D., Ceccarini J., Delva A., Robberecht W., Van Damme P., Van Laere K. Prospective validation of 18F-FDG brain PET discriminant analysis methods in the diagnosis of amyotrophic lateral sclerosis. Journal of Nuclear Medicine . 2016;57(8):1238&#x2013;1243. doi: 10.2967/jnumed.115.166272.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.115.166272</ArticleId><ArticleId IdType="pubmed">26940764</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A., Calvo A., Moglia C., et al. Brain 18fluorodeoxyglucose-positron emission tomography changes in amyotrophic lateral sclerosis with TARDBP mutations. Journal of Neurology, Neurosurgery, and Psychiatry . 2022;93(9):1021&#x2013;1023. doi: 10.1136/jnnp-2021-328296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-328296</ArticleId><ArticleId IdType="pubmed">35351820</ArticleId></ArticleIdList></Reference><Reference><Citation>Sennf&#xe4;lt S., Pagani M., Fang F., Savitcheva I., Estenberg U., Ingre C. FDG-PET shows weak correlation between focal motor weakness and brain metabolic alterations in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration . 2023;24(5-6):485&#x2013;494. doi: 10.1080/21678421.2023.2174881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2023.2174881</ArticleId><ArticleId IdType="pubmed">36755485</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A., Calvo A., Moglia C., et al. Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes. European Journal of Nuclear Medicine and Molecular Imaging . 2022;49(7):2242&#x2013;2250. doi: 10.1007/s00259-021-05668-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05668-7</ArticleId><ArticleId IdType="pmc">PMC9165265</ArticleId><ArticleId IdType="pubmed">35076740</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M., Chi&#xf2; A., Valentini M. C., et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology . 2014;83(12):1067&#x2013;1074. doi: 10.1212/WNL.0000000000000792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000792</ArticleId><ArticleId IdType="pubmed">25122207</ArticleId></ArticleIdList></Reference><Reference><Citation>Buhour M. S., Doidy F., Mondou A., et al. Voxel-based mapping of grey matter volume and glucose metabolism profiles in amyotrophic lateral sclerosis. EJNMMI Research . 2017;7(1):p. 21. doi: 10.1186/s13550-017-0267-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13550-017-0267-2</ArticleId><ArticleId IdType="pmc">PMC5339262</ArticleId><ArticleId IdType="pubmed">28266002</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laere K., Vanhee A., Verschueren J., et al. Value of 18fluorodeoxyglucose&#x2013;positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurology . 2014;71(5):553&#x2013;561. doi: 10.1001/jamaneurol.2014.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.62</ArticleId><ArticleId IdType="pubmed">24615479</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopalan V., Pioro E. P. 2-Deoxy-2-[18F]fluoro-d-glucose positron emission tomography, cortical thickness and white matter graph network abnormalities in brains of patients with amyotrophic lateral sclerosis and frontotemporal dementia suggest early neuronopathy rather than axonopathy. European Journal of Neurology . 2020;27(10):1904&#x2013;1912. doi: 10.1111/ene.14332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14332</ArticleId><ArticleId IdType="pubmed">32432818</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopalan V., Pioro E. P. Hypometabolic and hypermetabolic brain regions in patients with ALS-FTD show distinct patterns of grey and white matter degeneration: a pilot multimodal neuroimaging study. European Journal of Radiology . 2023;158, article 110616 doi: 10.1016/j.ejrad.2022.110616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejrad.2022.110616</ArticleId><ArticleId IdType="pubmed">36493498</ArticleId></ArticleIdList></Reference><Reference><Citation>Mat&#xed;as-Guiu J. A., Pytel V., Cabrera-Mart&#xed;n M. N., et al. Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging . 2016;43(11):2050&#x2013;2060. doi: 10.1007/s00259-016-3434-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-016-3434-1</ArticleId><ArticleId IdType="pubmed">27262702</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro A., Valentini M. C., Chi&#xf2; A., et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. European Journal of Nuclear Medicine and Molecular Imaging . 2012;39(2):251&#x2013;259. doi: 10.1007/s00259-011-1979-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-011-1979-6</ArticleId><ArticleId IdType="pubmed">22089661</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy J., Henry R., Lomen-Hoerth C. Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Archives of Neurology . 2007;64(3):330&#x2013;334. doi: 10.1001/archneur.64.3.330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.3.330</ArticleId><ArticleId IdType="pubmed">17353375</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory J. M., McDade K., Bak T. H., et al. Executive, language and fluency dysfunction are markers of localised TDP-43 cerebral pathology in non-demented ALS. Journal of Neurology, Neurosurgery &amp; Psychiatry . 2020;91(2):149&#x2013;157. doi: 10.1136/jnnp-2019-320807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320807</ArticleId><ArticleId IdType="pmc">PMC6996101</ArticleId><ArticleId IdType="pubmed">31515300</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala A., Iaccarino L., Fania P., et al. Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging . 2019;46(5):1117&#x2013;1131. doi: 10.1007/s00259-018-4246-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-018-4246-2</ArticleId><ArticleId IdType="pubmed">30617963</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vocht J., Van Weehaeghe D., Ombelet F., et al. Differences in cerebral glucose metabolism in ALS patients with and without C9orf72 and SOD1 mutations. Cells . 2023;12(6):p. 933. doi: 10.3390/cells12060933.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12060933</ArticleId><ArticleId IdType="pmc">PMC10047407</ArticleId><ArticleId IdType="pubmed">36980274</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanovello M., Sorar&#xf9; G., Campi C., et al. Brain stem glucose hypermetabolism in amyotrophic lateral sclerosis/frontotemporal dementia and shortened survival: an 18F-FDG PET/MRI Study. Journal of Nuclear Medicine . 2022;63(5):777&#x2013;784. doi: 10.2967/jnumed.121.262232.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.121.262232</ArticleId><ArticleId IdType="pubmed">34503963</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkett B. J., Babcock J. C., Lowe V. J., Graff-Radford J., Subramaniam R. M., Johnson D. R. PET imaging of dementia: update 2022. Clinical Nuclear Medicine . 2022;47(9):763&#x2013;773. doi: 10.1097/RLU.0000000000004251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RLU.0000000000004251</ArticleId><ArticleId IdType="pubmed">35543643</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P., Tang Y., Li W., et al. Brain metabolic signatures in patients with genetic and nongenetic amyotrophic lateral sclerosis. CNS Neuroscience &amp; Therapeutics . 2023;29(9):2530&#x2013;2539. doi: 10.1111/cns.14193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.14193</ArticleId><ArticleId IdType="pmc">PMC10401109</ArticleId><ArticleId IdType="pubmed">36971206</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A., Martino A., Giuliani A., et al. Brain metabolic differences between pure bulbar and pure spinal ALS: a 2-[18F]FDG-PET study. Journal of Nuclear Medicine . 2023;270(2):953&#x2013;959. doi: 10.1007/s00415-022-11445-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11445-9</ArticleId><ArticleId IdType="pmc">PMC9886651</ArticleId><ArticleId IdType="pubmed">36322237</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopalan V., Pioro E. P. Comparing brain structural MRI and metabolic FDG-PET changes in patients with ALS-FTD: 'the chicken or the egg?' question. Journal of Neurology, Neurosurgery &amp; Psychiatry . 2015;86(9):952&#x2013;958. doi: 10.1136/jnnp-2014-308239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-308239</ArticleId><ArticleId IdType="pubmed">25520437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward J., Ly M., Raji C. A. Brain PET imaging: frontotemporal dementia. PET Clinics . 2023;18(1):123&#x2013;133. doi: 10.1016/j.cpet.2022.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpet.2022.09.010</ArticleId><ArticleId IdType="pmc">PMC9884902</ArticleId><ArticleId IdType="pubmed">36442960</ArticleId></ArticleIdList></Reference><Reference><Citation>Renard D., Collombier L., Castelnovo G., Fourcade G., Kotzki P. O., LaBauge P. Brain FDG-PET changes in ALS and ALS-FTD. Acta Neurologica Belgica . 2011;111(4):306&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">22368970</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F., Altomare D., Festari C., et al. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. European Journal of Nuclear Medicine and Molecular Imaging . 2018;45(9):1546&#x2013;1556. doi: 10.1007/s00259-018-4033-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-018-4033-0</ArticleId><ArticleId IdType="pubmed">29717332</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelnovo V., Caminiti S. P., Riva N., Magnani G., Silani V., Perani D. Heterogeneous brain FDG-PET metabolic patterns in patients with C9orf72 mutation. Neurological Sciences . 2019;40(3):515&#x2013;521. doi: 10.1007/s10072-018-3685-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3685-7</ArticleId><ArticleId IdType="pubmed">30554355</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A., Moglia C., Manera U., et al. Metabolic brain changes across different levels of cognitive impairment in ALS: a 18F-FDG-PET study. Journal of Neurology, Neurosurgery &amp; Psychiatry . 2021;92(4):357&#x2013;363. doi: 10.1136/jnnp-2020-323876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323876</ArticleId><ArticleId IdType="pubmed">33229451</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A., Calvo A., Moglia C., et al. Brain metabolic changes across King's stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-D-glucose-positron emission tomography study. European Journal of Nuclear Medicine and Molecular Imaging . 2021;48(4):1124&#x2013;1133. doi: 10.1007/s00259-020-05053-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-05053-w</ArticleId><ArticleId IdType="pmc">PMC8041703</ArticleId><ArticleId IdType="pubmed">33029654</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A., Vacchiano V., D'Ovidio F., et al. Brain metabolic correlates of apathy in amyotrophic lateral sclerosis: an 18F-FDG-positron emission tomography stud. European Journal of Neurology . 2021;28(3):745&#x2013;753. doi: 10.1111/ene.14637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14637</ArticleId><ArticleId IdType="pubmed">33175462</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A., Martino A., Manera U., et al. Role of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging . 2023;50(3):784&#x2013;791. doi: 10.1007/s00259-022-05987-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-05987-3</ArticleId><ArticleId IdType="pmc">PMC9852209</ArticleId><ArticleId IdType="pubmed">36308536</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D., Devrome M., Schramm G., et al. Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics. European Journal of Nuclear Medicine and Molecular Imaging . 2020;47(11):2681&#x2013;2690. doi: 10.1007/s00259-020-04786-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-04786-y</ArticleId><ArticleId IdType="pubmed">32314027</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller Herde A., Schibli R., Weber M., Ametamey S. M. Metabotropic glutamate receptor subtype 5 is altered in LPS-induced murine neuroinflammation model and in the brains of AD and ALS patients. European Journal of Nuclear Medicine and Molecular Imaging . 2019;46(2):407&#x2013;420. doi: 10.1007/s00259-018-4179-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-018-4179-9</ArticleId><ArticleId IdType="pubmed">30291374</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownell A. L., Kuruppu D., Kil K. E., et al. PET imaging studies show enhanced expression of mGluR5 and inflammatory response during progressive degeneration in ALS mouse model expressing SOD1-G93A gene. Journal of Neuroinflammation . 2015;12(1):p. 217. doi: 10.1186/s12974-015-0439-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0439-9</ArticleId><ArticleId IdType="pmc">PMC4657381</ArticleId><ArticleId IdType="pubmed">26597638</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfc;rcher N. R., Loggia M. L., Lawson R., et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [11C]-PBR28. NeuroImage: Clinical . 2015;7:409&#x2013;414. doi: 10.1016/j.nicl.2015.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2015.01.009</ArticleId><ArticleId IdType="pmc">PMC4310932</ArticleId><ArticleId IdType="pubmed">25685708</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho M. J., Z&#xfc;rcher N. R., Loggia M. L., et al. Integrated magnetic resonance imaging and [11C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Annals of Neurology . 2018;83(6):1186&#x2013;1197. doi: 10.1002/ana.25251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25251</ArticleId><ArticleId IdType="pmc">PMC6105567</ArticleId><ArticleId IdType="pubmed">29740862</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D., Babu S., De Vocht J., et al. Moving toward multicenter therapeutic trials in amyotrophic lateral sclerosis: feasibility of data pooling using different translocator protein PET radioligands. Journal of Nuclear Medicine . 2020;61(11):1621&#x2013;1627. doi: 10.2967/jnumed.119.241059.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.119.241059</ArticleId><ArticleId IdType="pmc">PMC9364895</ArticleId><ArticleId IdType="pubmed">32169920</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratai E. M., Alshikho M. J., Z&#xfc;rcher N. R., et al. Integrated imaging of [11C]-PBR28 PET, MR diffusion and magnetic resonance spectroscopy 1H-MRS in amyotrophic lateral sclerosis. NeuroImage: Clinical . 2018;20:357&#x2013;364. doi: 10.1016/j.nicl.2018.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2018.08.007</ArticleId><ArticleId IdType="pmc">PMC6092554</ArticleId><ArticleId IdType="pubmed">30112276</ArticleId></ArticleIdList></Reference><Reference><Citation>Makary M. M., Weerasekara A., Rodham H., et al. Comparison of two clinical upper motor neuron burden rating scales in ALS using quantitative brain imaging. ACS Chemical Neuroscience . 2021;12(5):906&#x2013;916. doi: 10.1021/acschemneuro.0c00772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00772</ArticleId><ArticleId IdType="pubmed">33576234</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M. R., Cagnin A., Turkheimer F. E., et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiology of Disease . 2004;15(3):601&#x2013;609. doi: 10.1016/j.nbd.2003.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2003.12.012</ArticleId><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Tondo G., Iaccarino L., Cerami C., et al. 11 C-PK11195 PET-based molecular study of microglia activation in SOD1 amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology . 2020;7(9):1513&#x2013;1523. doi: 10.1002/acn3.51112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51112</ArticleId><ArticleId IdType="pmc">PMC7480909</ArticleId><ArticleId IdType="pubmed">32762033</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargiulo S., Anzilotti S., Coda A. R., et al. Imaging of brain TSPO expression in a mouse model of amyotrophic lateral sclerosis with 18F-DPA-714 and micro-PET/CT. European Journal of Nuclear Medicine and Molecular Imaging . 2016;43(7):1348&#x2013;1359. doi: 10.1007/s00259-016-3311-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-016-3311-y</ArticleId><ArticleId IdType="pubmed">26816193</ArticleId></ArticleIdList></Reference><Reference><Citation>James M. L., Fulton R. R., Vercoullie J., et al. DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. Journal of Nuclear Medicine . 2008;49(5):814&#x2013;822. doi: 10.2967/jnumed.107.046151.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.107.046151</ArticleId><ArticleId IdType="pubmed">18413395</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson A., Engler H., Blomquist G., et al. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. Journal of the Neurological Sciences . 2007;255(1-2):17&#x2013;22. doi: 10.1016/j.jns.2007.01.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.01.057</ArticleId><ArticleId IdType="pubmed">17346749</ArticleId></ArticleIdList></Reference><Reference><Citation>Saitoh Y., Imabayashi E., Mukai T., Matsuda H., Takahashi Y. Visualization of motor cortex involvement by 18F-THK5351 PET potentially strengthens diagnosis of amyotrophic lateral sclerosis. Clinical Nuclear Medicine . 2021;46(3):243&#x2013;245. doi: 10.1097/RLU.0000000000003456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RLU.0000000000003456</ArticleId><ArticleId IdType="pubmed">33323735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng K. P. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimer's Research &amp; Therapy . 2017;9(1):p. 25. doi: 10.1186/s13195-017-0253-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0253-y</ArticleId><ArticleId IdType="pmc">PMC5374697</ArticleId><ArticleId IdType="pubmed">28359327</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashihara M., Ishibashi K., Tokumaru A. M., Iwata A., Ishii K. 18F-THK5351 PET can identify core lesions in different amyotrophic lateral sclerosis phenotypes. Clinical Nuclear Medicine . 2021;46(12):e582&#x2013;e583. doi: 10.1097/RLU.0000000000003755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RLU.0000000000003755</ArticleId><ArticleId IdType="pubmed">34115705</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider A., Spinelli F., Herde A. M., et al. Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6/2 chorea Huntington mouse model and human ALS spinal cord tissue. European Journal of Medicinal Chemistry . 2018;145:746&#x2013;759. doi: 10.1016/j.ejmech.2017.12.097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2017.12.097</ArticleId><ArticleId IdType="pubmed">29353725</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu L., Bieri D., Slavik R., et al. Radiolabeling and in vitro/in vivo evaluation of. N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor. Journal of Neurochemistry . 2013;126(5):616&#x2013;624. doi: 10.1111/jnc.12354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12354</ArticleId><ArticleId IdType="pubmed">23795580</ArticleId></ArticleIdList></Reference><Reference><Citation>Wicks P., Turner M. R., Abrahams S., et al. Neuronal loss associated with cognitive performance in amyotrophic lateral sclerosis: an (11C)-flumazenil PET study. Amyotrophic Lateral Sclerosis . 2008;9(1):43&#x2013;49. doi: 10.1080/17482960701737716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701737716</ArticleId><ArticleId IdType="pubmed">18270878</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd C. M., Richardson M. P., Brooks D. J., Al-Chalabi A., Leigh P. N. Extramotor involvement in ALS: PET studies with the GABAA ligand [11C]flumazenil. Brain . 2000;123(11):2289&#x2013;2296. doi: 10.1093/brain/123.11.2289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/123.11.2289</ArticleId><ArticleId IdType="pubmed">11050028</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M. R., Rabiner E. A., Hammers A., et al. [11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain . 2005;128(4):896&#x2013;905. doi: 10.1093/brain/awh428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh428</ArticleId><ArticleId IdType="pubmed">15689356</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu X., Zhu W., Guo Z., et al. 18F-fallypride PET-CT of dopamine D2/D3 receptors in patients with sporadic amyotrophic lateral sclerosis. Journal of the Neurological Sciences . 2017;377:79&#x2013;84. doi: 10.1016/j.jns.2017.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2017.03.013</ArticleId><ArticleId IdType="pubmed">28477714</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y., Liu P., Li W., et al. Detection of changes in synaptic density in amyotrophic lateral sclerosis patients using 18F-SynVesT-1 positron emission tomography. European Journal of Neurology . 2022;29(10):2934&#x2013;2943. doi: 10.1111/ene.15451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15451</ArticleId><ArticleId IdType="pubmed">35708508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed H., Wallimann R., Haider A., et al. Preclinical development of 18F-OF-NB1 for imaging GluN2B-containing N-methyl-d-aspartate receptors and its utility as a biomarker for amyotrophic lateral sclerosis. Journal of Nuclear Medicine . 2021;62(2):259&#x2013;265. doi: 10.2967/jnumed.120.246785.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.120.246785</ArticleId><ArticleId IdType="pubmed">32737247</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight A. C., Morrone C. D., Varlow C., Yu W. H., McQuade P., Vasdev N. Head-to-head comparison of tau-PET radioligands for imaging TDP-43 in post-mortem ALS brain. Molecular Imaging and Biology . 2023;25(3):513&#x2013;527. doi: 10.1007/s11307-022-01779-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11307-022-01779-1</ArticleId><ArticleId IdType="pubmed">36258099</ArticleId></ArticleIdList></Reference><Reference><Citation>Colletti T., Agnello L., Spataro R., et al. Prognostic role of CSF &#x3b2;-amyloid 1-42/1-40 ratio in patients affected by amyotrophic lateral sclerosis. Brain Sciences . 2021;11(3):p. 302. doi: 10.3390/brainsci11030302.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11030302</ArticleId><ArticleId IdType="pmc">PMC7997395</ArticleId><ArticleId IdType="pubmed">33673569</ArticleId></ArticleIdList></Reference><Reference><Citation>Borasio G. D., Linke R., Schwarz J., et al. Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT single photon emission computed tomography. Journal of Neurology, Neurosurgery &amp; Psychiatry . 1998;65(2):263&#x2013;265. doi: 10.1136/jnnp.65.2.263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.65.2.263</ArticleId><ArticleId IdType="pmc">PMC2170216</ArticleId><ArticleId IdType="pubmed">9703186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa T., Morita M., Nakano I. Constant blood flow reduction in premotor frontal lobe regions in ALS with dementia - a SPECT study with 3D-SSP. Acta Neurologica Scandinavica . 2007;116(5) doi: 10.1111/j.1600-0404.2007.00876.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2007.00876.x</ArticleId><ArticleId IdType="pubmed">17922728</ArticleId></ArticleIdList></Reference><Reference><Citation>Habert M. O., Lacomblez L., Maksud P., El Fakhri G., Pradat J. F., Meininger V. Brain perfusion imaging in amyotrophic lateral sclerosis: extent of cortical changes according to the severity and topography of motor impairment. Amyotrophic Lateral Sclerosis . 2007;8(1):9&#x2013;15. doi: 10.1080/14660820601048815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820601048815</ArticleId><ArticleId IdType="pubmed">17364429</ArticleId></ArticleIdList></Reference><Reference><Citation>Shindo A., Ueda Y., Kuzuhara S., Kokubo Y. Neuropsychological study of amyotrophic lateral sclerosis and parkinsonism-dementia complex in Kii Peninsula, Japan. BMC Neurology . 2014;14(1):p. 151. doi: 10.1186/1471-2377-14-151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-14-151</ArticleId><ArticleId IdType="pmc">PMC4107997</ArticleId><ArticleId IdType="pubmed">25041813</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto N., Kurata T., Sato K., Ikeda Y., Sato S., Abe K. Frontal dysfunctions of ALS-PBP patients in relation to their bulbar symptoms and rCBF decline. Journal of the Neurological Sciences . 2012;319(1-2):96&#x2013;101. doi: 10.1016/j.jns.2012.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2012.04.020</ArticleId><ArticleId IdType="pubmed">22613760</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldemar G., Vorstrup S., Jensen T. S., Johnsen A., Boysen G. Focal reductions of cerebral blood flow in amyotrophic lateral sclerosis: a [99mTc]-d,l-HMPAO SPECT study. Journal of the Neurological Sciences . 1992;107(1):19&#x2013;28. doi: 10.1016/0022-510x(92)90204-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510x(92)90204-x</ArticleId><ArticleId IdType="pubmed">1578230</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercelletto M., Ronin M., Huvet M., Magne C., Feve J. R. Frontal type dementia preceding amyotrophic lateral sclerosis: a neuropsychological and SPECT study of five clinical cases. European Journal of Neurology . 1999;6(3):295&#x2013;299. doi: 10.1046/j.1468-1331.1999.630295.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1468-1331.1999.630295.x</ArticleId><ArticleId IdType="pubmed">10210909</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Fujimura H., Toyooka K., Sakoda S., Yorifuji S., Yanagihara T. Cognitive function in amyotrophic lateral sclerosis. Journal of the Neurological Sciences . 1997;138(1):95&#x2013;100. doi: 10.1016/S0022-510X(96)05338-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(96)05338-5</ArticleId><ArticleId IdType="pubmed">9125395</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>